Characteristics and treatment of hypertension in women: A review of the literature

American Journal of the Medical Sciences

Volumn 311, Issue 4, 1996, Pages 193-199

  Lewis, Cora E ^a,b  

^a University of Alabama at Birmingham   (United States)

^b NONE   (United States)

Author keywords

Blood pressure; Cardiovascular disease; Gender; Women

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

DRUG EFFICACY; HUMAN; HYPERTENSION; LIPOPROTEIN METABOLISM; PLASMA RENIN ACTIVITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME;

EID: 0029927578     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199604000-00010     Document Type: Review

References (89)

1. Anastos K, Charney P, Charon RA, Charon RA, Cohen E, Jones CY, et al. Hypertension in women: What is really known? Ann Intern Med. 1991;115:287-93.
2. Kitler ME. Differences in men and women in coronary artery disease, systemic hypertension and their treatment. Am J Cardiol. 1992;70:1077-80.
3. NIH Guidelines on the inclusion of women and minorities as subjects in clinical research; Notice. Federal Register. March 28, 1994;59:14508-13.
4. FDA Plans Policy Change on Women in Clinical Trials. Rockville, MD: Food and Drug Administration; April 1993:1-2. US Dept of Health and Human Services FDA Talk Paper T93-18.
5. Kuller LH, Meilahn EN, Cauley JA, Gutai JP, Matthews KA. Epidemiologic studies of menopause: Changes in risk factors and disease. Exp Gerontol. 1994;29:495-509.
6. Owens JF, Stoney CM, Matthews KA. Menopausal status influences ambulatory blood pressure levels and blood pressure changes during mental stress. Circulation. 1993;88:2794-2802.
7. Lindheim SR, Legro RS, Bernstein L, Stanczyk FZ, Vijod MA, Presser SC, et al. Behavioral stress responses in premenopausal and postmenopausal women and the effects of estrogen. Am J Obstet Gynecol. 1992;167:1831-6.
8. Wu ZY, Wu XK, Ahang YW. Relationship of menopausal status and sex hormones to serum lipids and blood pressure. Int J Epidemiol. 1990;19:297-302.
9. Kaplan NM. Renovascular hypertension and renin-secreting tumors. Clinical Hypertension, 2nd ed. Baltimore: Williams & Wilkins; 1978:218-60.
10. Krakoff LR. Hypertension in women: Progress and unsolved problems. Women Health. 1985;10:75-83.
11. Meade TW, Imerson JD, Gordon D, Peart WS. The epidemiology of plasma renin. Clin Sci. 1983;64:273-80.
12. Ganguli A, Weinberger MH. Low renin hypertension: A review of definitions and controversies. Am Heart J. 1979;98:642-52.
13. Sealey JE, Atlas SA, Glorioso N, Manapat H, Laragh JH. Cyclical secretion of prorenin during the menstrual cycle: Synchronization with luteinizing hormone and progesterone. Proc Natl Acad Sci USA. 1985;82:8705-9.
14. Dunne FP, Barry DG, Ferriss JB, Grealy G, Murphy D. Changes in blood pressure during the normal menstrual cycle. Clin Sci. 1991;81:515-8.
15. Massie BM. Demographic considerations in the selection of antihypertensive therapy. Am J Cardiol. 1987;60:121I-6I.
16. Karpanou EA, Vyssoulis GP, Georgoudi DG, Toutouza MG, Toutouzas PK. Ambulatory blood pressure changes in the menstrual cycle of hypertensive women. Am J Hypertens. 1993;6:654-9.
17. Messerli FH, Garavaglia GE, Schmieder RE, Sundaard-Riise K, Nunez BD, Amodeo C. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987;107:158-61.
18. Messerli FH, Sundgaard-Riise K, Ventura HO, Dunn FG, Glade LB. Essential hypertension in the elderly: Hemodynamics, intravascular volume, plasma renin activity and circulating catecholamine levels. Lancet. 1983;2:983-8.
19. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383-90.
20. Matthews K, Meilahn E, Kuller L, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med. 1989;321:641-6.
21. Barrett-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 1990;10:531-4.
22. Jiang C, Sarrel P, Poole-Wilson P, Collins P. Acute effect of 17β-estradion on rabbit coronary artery contractile responses to endothelin-1. Am J Physiol. 1992;263:H271-5.
23. Sack MN, Raden DJ, Cannon RO 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-70.
24. de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23:600-6.
25. Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res. 1987;48:621-30.
26. Francis RB, Kawanishi D, Baruch T, Mahrer P; Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J. 1988;115:776-80.
27. Nordby G, Haaland A, Os I. Evidence of decreased fibrinolytic activity in hypertensive pre-menopausal women. Scand J Clin Lab Invest. 1992;52:275-81.
28. Glueck CJ, Glueck HI, Hamer T, Speirs J, Tracy T, Stroop D. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity. Am J Med Sci. 1994;307:317-24.
29. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: Prevailing assumptions and outstanding questions. Am Heart J. 1987;114:1467-1503.
30. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective studies. Circulation. 1989;79:8-15.
31. Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J. 1986;112:432-7.
32. Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Rybo E. Triglycerides: Main risk factor for cardiovascular disease in women? Acta Med Scand. 1985;217:481-9.
33. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Brangdiwala S. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328:1220-5.
34. MacMahon SW, MacDonald GJ. Antihypertensive treatment and plasma lipoprotein levels. Am J Med. 1986;80(suppl 2A): 40-7.
35. Maxwell MH, Fitzsimmons E, Harrist R, Hotchkiss J, Langford HG, Payne GH, et al. Baseline laboratory examination characteristics of the hypertensive participants. Hypertension Detection and Follow-up Program. Hypertension. 1983;5(suppl 4):133-59.
36. Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, et al. Antihypertensive drugs and blood lipids: The Oslo Study. J Cardiovasc Pharmacol. 1982;4(suppl 2):S222-4.
37. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: The Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med. 1993;153: 154-83.
38. Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, et al. Effect of antihypertensives on sexual function and quality of life: The TAIM Study. Ann Intern Med. 1991;114:613-20.
39. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among U.S. adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-11.
40. Kramer FM, Jeffrey RW, Forester JL, Snell MK. Long-term follow-up of behavioral treatment for obesity: Patterns of weight regain among men and women. Int J Obes. 1989;13:123-36.
41. Foreyt JP, Goodrick GK, Gotto AM. Limitations of behavioral treatment of obesity: Review and analysis. J Behav Med. 1981;4:159-74.
42. Nestel PJ, Clifton PM, Noakes M, McArthur R, Howe PR. Enhanced blood pressure response to dietary salt in elderly women, especially those with small waist:hip ratio. J Hypertens. 1993;11:1387-94.
43. Kumanyika SK, Hebert PR, Cutler JA, Iasser VI, Sugars CP, Steffen-Gatey L, et al. Feasibility and efficacy of sodium reduction in the Trials of Hypertension Prevention, phase I. Trials of Hypertension Prevention Collaborative Research Group. Hypertension. 1993;22:502-12.
44. Kotchen JM, Cox-Ganser J, Wright CJ, Kotchen TA. Gender differences in obesity-related cardiovascular disease risk factors among participants in a weight loss programme. Int J Obes. 1993;17:145-51.
45. The Australian therapeutic trial in mild hypertension. Report by the Management Committee. Lancet. 1980;1:1261-7.
46. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 1985;291: 97-104.
47. Massie BM, MacCarthy EP, Ramanathan KB, Weiss RJ, Anderson M, Eidelson BA, et al. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med. 1987;107:150-7.
48. Buhler FR. Antihypertensive treatment according to age, plasma renin, and race. Drugs. 1988;35:495-503.
49. LaCroix AZ, Wienpahl J, White LR, Wallace RB, Scherr PA, George LK, et al. Epidemiology, Demography, and Biometry Program, National Institute on Aging, Bethesda, MD. N Engl J Med. 1990;322:286-90.
50. Cauley JA, Cummings SR, Seeley DG, Black D, Browner W, Kuller LH, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1993;118:666-73.
51. Fenakel K, Lurie S. The use of calcium channel blockers in obstetrics and gynecology: A review. Eur J Obstet Gynecol Reprod Biol. 1990;37:199-203.
52. Hanssens M, Keirse MJ, Vankelecom F, VanAssche FA. Fetal and neonatal effects of treatment with angiotensin-converting enzyme inhibitors in pregnancy. Obstet Gynecol. 1991;78: 128-35.
53. Kreft-Jais C, Plouin PF, Tchobroutsky C, Boutroy MJ. Angiotensin-converting enzyme inhibitors during pregnancy: A survey of 22 patients given captopril and nine given enalapril. Br J Obstet Gynaecol. 1988;95:420-2.
54. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: I. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA. 1967;202:1028-34.
55. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: H. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA. 1970;213:1143-52.
56. Helgeland A. Treatment of mild hypertension: A five-year controlled drug trial. The Oslo Study. Am J Med. 1980;69:725-32.
57. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA. 1982;248:1465-77.
58. Hypertension Detection and Follow-up Program Cooperative Group (1979): Five-year findings of the Hypertension Detection and Follow-up Program: II. Mortality by race, sex and age. JAMA. 1979;242:2572-7.
59. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;1:1349-54.
60. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
61. Dahlöf B, Hansson L, Lindholm LH, Scherstén B, Ekbom T, Wester P-O. Swedish trial in old patients with hypertension (STOP-Hypertension): Analyses performed up to 1992. Clin Exp Hypertens. 1993;15:925-39.
62. Browner WS, Hulley SB. Effect of risk status on treatment criteria. Implications of hypertension trials. Hypertension. 1989;13(suppl 5):I51-6.
63. Jackson R, Barbara P, Bills J, Birch T, McLennan L, MacMahon S, et al. Management of raised blood pressure in New Zealand: A discussion document. BMJ. 1993;307:107-10.
64. Aylett M, Ketchin S. Stopping treatment in patients with hypertension. BMJ. 1991;303:45.
65. Nadal M, Wikström L, Allgulander S. Once hypertensive, always hypertensive? A three-year follow-up after stopping medication. Scand J Prim Health Care. 1994;12:62-4.
66. Grimm R, Svendsen K, Elmer P, Grandits G, Prinaes R, Cutler J, et al. Results of drug tolerance, quality of life, and side effects in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1994;90:I665.
67. Abramow M, Cogan E. Clinical aspects and pathophysiology of diuretic-induced hyponatremia. Adv Nephrol. 1984;13:1-28.
68. Van Gilst WH, Tussen JGP, Van Es GA, Lubsen J. Serum potassium values in relation to the use of diuretics in patients with unstable angina pectoris. Eur Heart J. 1988;9:795-9.
69. Lawson DH, Henry DA, Lowe JM, Gray JM, Morgan HG. Severe hypokalaemia in hospitalized patients. Arch Intern Med. 1979;139:978-80.
70. Gibson GR. Enalapril-induced cough. Arch Intern Med. 1989;149:2701-3.
71. Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen J, Tretli S. Female sex as an important determinant of lisinopril-induced cough. Lancet. 1992;339:372.
72. Heckerling PS. Enalapril and vulvovaginal pruritus. Ann Intern Med. 1990;112:879-80.
73. ®. 1995:1877.
74. Wood Sm, Mann RD, Rawlins MD. Angio-edema and urticaria associated with angiotensin converting enzyme inhibitors. BMJ. 1987;294:91-2.
75. Slater EE, Merrill DD, Guess HA, Roylance PJ, Cooper WD, Inman WH, et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA. 1988;260: 967-70.
76. Hedner T, Samuelsson O, Lindholm L, Andrén L, Wilholm B. Precipitation of angioedema by antihypertensive drugs. J Hypertens. 1991;9(suppl 6):S360-1.
77. Boehringer K, Weidmann P, Mordasini R, Schiffl H, Bachmann C, Reisen W. Menopause-dependent plasma lipoprotein alterations in diuretic-treated women. Ann Intern Med. 1982;97:206-9.
78. Szollár LG, Mészáos I, Tornóci L, Rischák K, Molnár M, Mánya S. Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females. J Cardiovasc Pharmacol. 1990;15:911-7.
79. Prisant LM, Carr AA, Bottini PB, Solursh DS, Solursh LP. Sexual dysfunction with antihypertensive drugs. Arch Intern Med. 1994;154:730-6.
80. Poloniecki J, Hamilton M. Subjective costs of antihypertensive treatment. Hum Toxicol. 1985;4:287-91.
81. Riley AJ, Steiner JA, Cooper R, McPherson CK. The prevalence of sexual dysfunction in male and female hypertensive patients. Sex Marital Ther. 1987;2:131-8.
82. Bulpitt CJ, Beevers DG, Butler A, Coles EC, Hunt D, Munro-Faure AD, et al. The effects of anti-hypertensive drugs on sexual function in men and women: A report from the DHSS Hypertension Care Computing Project (DHCCP). J Hum Hypertens. 1989;3:53-6.
83. Watts RJ. Sexual functioning, health beliefs and compliance with high blood pressure medications. Nurs Res. 1982;31:278-83.
84. Duncan L, Bateman DN. Sexual function in women: Do antihypertensive drugs have an impact? Drug Safety. 1993;8:225-34.
85. Marley JE, Curram JB. General practice data derived tolerability assessment of antihypertensive drugs. J Int Med Res. 1989;17:473-8.
86. Schoenberger JA, Testa M, Ross AD, Brennan WK, Bannon JA. Efficacy, safety and quality-of-life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med. 1990;150:301-6.
87. Walle T, Byington RP, Furberg CD, McIntyre KM, Vokonas PS. Biologic determinants of propranolol disposition: Results from 1308 patients in the beta-blocker heart attack trial. Clin Pharmacol Ther. 1985;38:509.
88. Walle T, Walls Uk, Cowart D, et al. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther. 1989;46:257-63.
89. Turkington RW. Prolactin secretion in patients treated with various drugs. Arch Intern Med. 1972;130:349-57.